首页 Clovis肿瘤药物(usCLVS)-基本信息

Clovis肿瘤药物(usCLVS)-基本信息

日报更新时间:04-10 10:00

周报更新时间:04-11 03:39

行情信息

今开价:6.21

最高价:6.22

成交量:3951749.0

昨收价:6.23

最低价:5.98

最新价:6.16

行情图标
概要信息

中文名称:Clovis肿瘤药物


英文名称:Clovis Oncology


简介:Clovis Oncology, Inc.是一家处于开发阶段的公司,2009年4月20日在美国特拉华州注册成立,正式开始运作于2009年5月


电话:1-303-6255000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Clovis Oncology公司主要从事收购美国、欧洲及其他国际市场的创新抗癌药物,目前正在研发三种抗癌药物产品:治疗胰腺癌的「CO-101」 、表皮生长因子受体口服制剂「CO-1686」、PARP抑制剂「CO-338」,Clovis Oncology公司至今还未取得任何收入。2015年11月16日,因FDA要求Clovis Oncology提供药物实验补充数据,CLVS暴跌69%,股价由99美金一路狂泻至28美金,收于30美金。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-28 Klingenstein (Paul H) Director Buy 25862 0.29
2019-06-19 Rolfe (Lindsey) Officer Buy 3438 --
2019-06-19 Ivers-Read (Gillian C) Officer Buy 1875 --
2019-06-19 Ivers-Read (Gillian C) Officer Sell 829 14.70
2019-06-19 Rolfe (Lindsey) Officer Sell 1728 14.70
2019-06-03 Gross (Paul Edward) General Counsel Buy 562 --
2019-06-03 Muehl Daniel W Chief Financial Officer Buy 468 --
2019-06-03 Rolfe (Lindsey) Officer Sell 312 15.07
2019-06-03 Rolfe (Lindsey) Officer Sell 343 15.07
2019-06-03 Rolfe (Lindsey) Officer Buy 625 --
2019-06-03 Rolfe (Lindsey) Officer Buy 687 --
2019-06-03 Muehl Daniel W Chief Financial Officer Sell 247 15.07
2019-06-03 Muehl Daniel W Chief Financial Officer Sell 206 15.07
2019-06-03 Muehl Daniel W Chief Financial Officer Buy 562 --
2019-06-03 Gross (Paul Edward) General Counsel Buy 468 --
2019-06-03 Gross (Paul Edward) General Counsel Sell 247 15.07
2019-06-03 Gross (Paul Edward) General Counsel Sell 206 15.07
2019-06-03 Ivers-Read (Gillian C) Officer Sell 302 15.07
2019-06-03 Ivers-Read (Gillian C) Officer Buy 625 --
2019-06-03 Ivers-Read (Gillian C) Officer Sell 275 15.07
2019-06-03 Ivers-Read (Gillian C) Officer Buy 687 --
2019-05-28 Muehl Daniel W Chief Financial Officer Sell 271 14.88
2019-05-28 Muehl Daniel W Chief Financial Officer Buy 547 --
2019-03-19 Rolfe (Lindsey) Officer Buy 3437 --
2019-03-19 Rolfe (Lindsey) Officer Sell 1729 26.13

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Candriam Luxembourg S.C.A. 781623 1.43% 488523 166.67% 2019-03-31
BlackRock Fund Advisors 2169935 3.98% -2093 -0.10% 2019-07-31
Orbimed Advisors, LLC 2832300 5.20% 80100 2.91% 2019-03-31
State Street Corporation 3402443 6.24% 6854 0.20% 2019-03-31
SSGA Funds Management Inc 4240876 7.78% 81977 1.97% 2019-07-31
BlackRock Inc 4275846 7.85% -74312 -1.71% 2019-03-31
Redmile Group, LLC 4563929 8.38% 503400 12.40% 2019-03-31
Vanguard Group Inc 4629762 8.50% 68832 1.51% 2019-03-31
Palo Alto Investors, LLC 5239304 9.62% -- -- 2019-03-31
Armistice Capital, LLC 2100000 3.85% -2936000 -58.30% 2019-03-31
Capital Research and Management Company 1879037 3.45% 1227037 188.20% 2019-07-31
Camber Capital Management LLC 1500000 2.75% -1300000 -46.43% 2019-03-31
Westfield Capital Management Company, LP 806465 1.48% 806465 -- 2019-03-31
Candriam Belgium 891100 1.64% 220000 32.78% 2019-07-31
Fidelity Management and Research Company 892043 1.64% -143152 -13.83% 2019-03-31
FMR Inc 897343 1.65% -143152 -13.76% 2019-03-31
Northern Trust Investments Inc 966924 1.77% 9607 1.00% 2019-07-31
Carmignac Gestion 1092536 2.01% -5600 -0.51% 2019-07-31
Vanguard Investments Australia Ltd 1324753 2.43% 401227 43.45% 2019-07-31
Healthcor Management LP 1398300 2.57% 1398300 -- 2019-03-31
Spark Investment Management LLC 673100 1.27% 227800 51.16% 2019-03-31
Citadel Advisors Llc 675070 1.27% 63138 10.32% 2019-03-31
Fidelity SelectCo, LLC 767548 1.45% -246125 -24.28% 2019-06-30
Candriam Luxembourg 781623 1.47% 488523 166.67% 2019-03-31
PointState Capital LP 937676 1.77% -2005228 -68.14% 2018-12-31
BlackRock Asset Management Canada Ltd 1110721 2.10% 204 0.02% 2019-05-31
Geode Capital Management, LLC 1144008 2.16% 611373 114.78% 2018-12-31
Morgan Stanley - Brokerage Accounts 676970 1.28% 310448 84.70% 2018-12-31
ING Investment Management LLC 737188 1.39% -28432 -3.71% 2018-12-31
Putnam Investments LLC 985503 1.86% -91680 -8.51% 2018-12-31
Farallon Capital Management, L.L.C. 1000000 1.89% 1000000 -- 2018-12-31
Samlyn Capital, LLC 1005237 1.90% 1005237 -- 2018-12-31
Putnam Investment Management, LLC 1049560 1.98% -109384 -9.44% 2019-04-30
Franklin Advisers, Inc. 1757885 3.33% -492149 -21.87% 2018-09-30
Franklin Resources Inc 1761885 3.33% -494638 -21.92% 2018-09-30
venBio Select Advisor LLC 1146636 2.17% 200 0.02% 2018-09-30
Partner Fund Management LP 1927928 3.65% -409297 -17.51% 2018-09-30
AllianceBernstein L.P. 1414652 2.68% 461629 48.44% 2018-09-30
BlackRock Institutional Trust Company NA 1537539 2.92% 171391 12.55% 2018-06-30
State Street Corp 2473176 4.70% 400601 19.33% 2018-06-30
Franklin Advisers Inc 2250034 4.27% -233016 -9.38% 2018-06-30
Putnam Investment Management,LLC 1209308 2.30% 224335 22.78% 2018-06-30
AllianceBernstein LP 953023 1.81% -224954 -19.10% 2018-06-30
Close Finsbury Asset Management Limited 687400 1.31% -- -- 2018-05-31
Delaware Management Business Trust 691459 1.31% 75589 12.27% 2018-06-30
Capital World Investors 652000 1.29% 652000 -- 2018-03-31
Point72 Asset Management, L.P. 1155937 2.28% 279937 31.96% 2018-03-31
Jennison Associates LLC 690563 1.31% -7013 -1.01% 2018-06-30
Columbia Wanger Asset Management LLC 514996 1.02% -66664 -11.46% 2017-12-31
Northern Trust Investments N A 558175 1.10% -14580 -2.55% 2017-12-31
Fred Alger Management Inc 642709 1.27% -185698 -22.42% 2017-12-31
T. Rowe Price Associates, Inc. 883977 1.75% -468728 -34.65% 2017-12-31
Balyasny Asset Management LLC 499688 1.02% 53437 11.97% 2017-09-30
Macquarie Investment Management Limited 526880 1.08% 526880 -- 2017-09-30
D. E. Shaw & Co LP 1079731 2.21% -554741 -33.94% 2017-06-30
Consonance Capital Management LP 3531487 9.15% 595000 20.26% 2016-09-30
Millennium Management LLC 2268090 5.88% 2268090 -- 2017-01-06
NEA Management Company, LLC 1139890 2.95% -- -- 2016-09-30
Goldman, Sachs & Co. 849820 2.20% -900507 -51.45% 2016-09-30
Morgan Stanley & Co Inc 715295 1.85% -488318 -40.57% 2016-09-30
Cormorant Asset Management, LLC 650000 1.68% 650000 -- 2016-09-30
Beneficial owners affiliated with Baker Bros. Advisors LP 2292325 4.00% 200555514 0.10% 1999-11-30
M. James Barrett 2280355 4.00% 199508259 0.10% 1999-11-30
James C. Blair 2191824 4.00% 191762682 0.10% 1999-11-30
BlackRock, Inc. 2160196 4.00% 188995548 0.10% 1999-11-30
Beneficial owners affiliated with Palo Alto Investors, LLC 2102857 4.00% 183978959 0.10% 1999-11-30
Beneficial owners affiliated with Partner Fund Management, LP 1871802 4.00% 163763957 -- 1999-11-30
Oppenheimer Funds, Inc. 1776974 4.00% 155467455 -- 1999-11-30
FMR LLC 3859599 4.00% 337676317 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
State Street Russell Small/Mid Cap 204386 0.37% -- -- 2019-06-30
SPDR 4193417 7.67% 82232 2.00% 2019-07-31
American Funds SMALLCAP World Fund 1879037 3.44% 1227037 188.20% 2019-06-30
Vanguard Total Stock Market Index Fund 1314212 2.40% 401288 43.96% 2019-06-30
Vanguard Small Cap Index 1299148 2.38% -8090 -0.62% 2019-06-30
iShares Russell 2000 ETF 1065330 1.95% 2090 0.20% 2019-07-30
Candriam Eqs L Biotechnology 849100 1.55% 220000 34.97% 2019-06-30
Vanguard Small Cap Growth Index Fund 743306 1.36% 2593 0.35% 2019-06-30
Vanguard Extended Market Index Fund 734308 1.34% -1586 -0.22% 2019-06-30
iShares Nasdaq Biotechnology ETF 523249 0.96% 7809 1.52% 2019-07-30
Swedbank Robur Medica 224000 0.41% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 451244 0.83% 8671 1.96% 2019-07-30
iShares Healthcare Innov ETF 294951 0.54% -- -- 2019-07-30
Fidelity 252289 0.46% -- -- 2019-06-30
Direxion Daily S&P Biotech Bull 3X Shrs 247783 0.45% 67246 37.25% 2019-04-30
CPR Invest Global Disruptive Opps 246300 0.45% -112300 -31.32% 2018-12-31
Sector Healthcare Fund 245432 0.45% -- -- 2019-06-30
Biotech Growth Trust Plc 229700 0.42% -45700 -16.59% 2019-04-30
Worldwide Healthcare 653600 1.20% -145400 -18.20% 2019-04-30
Carmignac Investissement 422404 0.80% -- -- 2018-09-30
Carmignac Patrimoine 942955 1.78% -- -- 2018-09-30
CREF Stock Account 272134 0.51% 45200 19.92% 2019-04-30
iShares US Small Cap ETF (CAD-Hedged) 964361 1.82% -1620 -0.17% 2019-05-30
Putnam Global Health Care Fund 236957 0.45% -65400 -21.63% 2019-03-31
Vanguard Small Cap Index Fund 1310878 2.47% 12696 0.98% 2019-04-30
NT R2000 Growth Index Fund - Non-Lending 207815 0.39% -- -- 2019-03-31
DFA US Micro Cap Portfolio 204867 0.39% -- -- 2019-03-31
Putnam Sustainable Leaders Fund 521200 0.98% -- -- 2018-12-31
State Street Russell Small Cap 200789 0.38% 8296 4.31% 2019-02-28
VA CollegeAmerica SMALLCAP Wld Fd 652000 1.23% -- -- 2018-12-31
Voya SmallCap Opportunities Fund 198102 0.38% 35788 22.05% 2018-09-30
Invesco Health Care Fund 234518 0.44% -- -- 2018-09-30
HBM Healthcare Investments AG 180000 0.34% -5482 -2.96% 2018-09-30
Delaware Small Cap Core Fund 390654 0.74% -271346 -40.99% 2018-10-31
ILI Franklin US Opportunities EUR 202342 0.38% -- -- 2018-07-31
RI CBF Dir AllianceBern Small Cap Gr 244460 0.46% 4770 1.99% 2018-09-30
RI CBF Dir AllianceBern Discovery Gr 317750 0.60% 15020 4.96% 2018-09-30
PGIM Jennison Health Sciences Fund 452321 0.86% -- -- 2018-07-31
Columbia Acorn Fund 367223 0.70% 132500 56.45% 2018-04-30
Franklin Biotechnology Discovery Fund 696600 1.32% -- -- 2018-09-30
iShares Nasdaq Biotechnology 597689 1.04% -1137 -0.19% 2018-09-12
Fidelity Advisor 204825 0.39% -24500 -10.68% 2018-07-31
Vanguard Total Stock Mkt Idx 1250356 2.37% 1196 0.10% 2018-07-31
Vanguard Small Cap Growth Index Inv 717531 1.36% 10790 1.53% 2018-07-31
Franklin Biotechnology Discovery A 696600 1.32% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 695642 1.32% 9000 1.31% 2018-07-31
Delaware Small Cap Core A 541900 1.03% 36000 7.12% 2018-07-31
Prudential Jennison Health Sciences A 452321 0.86% -- -- 2018-07-31
iShares Russell 2000 Growth 458009 0.80% -442 -0.10% 2018-09-12
Putnam Global Health Care A 293757 0.56% -70400 -19.33% 2018-06-30
State Street Russell Small/Mid Cap Idx Fd Cl I 130057 0.27% 9410 7.80% 2017-06-30
AB Small Cap Growth A 205400 0.39% 36870 21.88% 2018-07-31
T. Rowe Price QM US Small-Cap Growth Eq 199600 0.38% -13700 -6.42% 2018-06-30
Franklin Small Cap Growth A 211700 0.40% -- -- 2018-07-31
Fidelity Spartan 239204 0.45% 6778 2.92% 2018-07-31
Invesco Global Health Care A 234518 0.45% -- -- 2018-06-30
RI CBF AllianceBern Discovery Gr RA 255590 0.49% 62280 32.22% 2018-07-31
Harbor Small Cap Growth Instl 184720 0.35% 59940 48.04% 2018-06-30
Putnam Multi-Cap Growth A 353700 0.70% -- -- 2018-03-31
Franklin Growth Opportunities A 238808 0.45% -- -- 2018-05-31
Vanguard Small Cap Value Index Inv 357058 0.68% 3648 1.03% 2018-05-31
Columbia Acorn Z 367223 0.70% 132500 56.45% 2018-04-30
T. Rowe Price New Horizons 224408 0.44% -201000 -47.25% 2017-12-31
T. Rowe Price Health Sciences 240792 0.48% -235900 -49.49% 2017-12-31
CREF Stock R1 282141 0.56% -1433 -0.51% 2017-12-31
Touchstone Mid Cap Growth A 218470 0.57% 218470 -- 2016-12-31
TIAA-CREF Growth & Income Instl 198752 0.52% -- -- 2016-12-31
TIAA-CREF Small-Cap Equity Instl 160800 0.42% -- -- 2016-12-31
Schwab US Small-Cap ETF 87343 0.19% 162 0.19% 2017-02-08
JPMorgan US Small Company Instl 84600 0.22% 2100 2.55% 2016-12-31
Fidelity® Select Biotechnology Portfolio 938124 2.50% -- -- 2015-09-30
T. Rowe Price Health Sciences Fund 788395 2.10% -93000 -10.60% 2015-09-30
Oppenheimer Global Fund 675940 1.80% 1880 0.30% 2015-09-30
Bb Biotech AG 618188 1.60% -- -- 2015-09-30
T. Rowe Price New Horizons Fund 485281 1.30% -88288 -15.40% 2015-09-30
Fidelity® Growth Company Fund 453100 1.20% -5000 -1.10% 2015-09-30
iShares Russell 2000 (AU) 440893 0.30% -558 -0.10% 2015-11-19
Wells Fargo Advantage Discovery Fund 350600 0.90% 16300 4.90% 2015-09-30
Vanguard Small Cap Value Index Fund 339866 0.90% 5932 1.80% 2015-10-31
SPDR® S&P Biotech ETF 227394 0.20% 1484 0.70% 2015-11-19
Fidelity® OTC Portfolio 1053954 2.80% -- -- 2015-09-30

Gillian C. Ivers-Read Gillian C. Ivers-Read founded Clovis Oncology, Inc. Currently, she is Chief Regulatory Officer & Executive VP at this company. In her past career she was Executive Vice President-Development Operations at Pharmion Corp., Director-Regulatory Affairs at Marion Merrell Dow, Inc., Vice President-Development & Regulatory Affairs at Argus Pharmaceuticals, Inc., Vice President-Global Regulatory Affairs at Hoechst Marion Roussel, Inc. and Vice President-Global Regulatory Affairs at Aventis Pharmaceuticals, Inc. She received an undergraduate degree from University College London.
Daniel W. Muehl Currently, Daniel W. Muehl occupies the position of Chief Financial & Accounting Officer at Clovis Oncology, Inc. Mr. Muehl is also on the board of Clovis Oncology UK Ltd. In his past career Mr. Muehl was Chief Operating & Financial Officer for International Precious Minerals Group, Inc., Chief Financial Officer for SomaLogic, Inc., Chief Financial Officer for Repligen Corp., Principal at Horwath Velez & Co. PSC, Chief Financial Officer for Physiometrix, Inc., Vice President-Finance at Pharmion Corp., Chief Financial Officer at OPX Biotechnologies, Inc. and Principal at Ernst & Young LLP. Daniel W. Muehl received an undergraduate degree from the University of Massachusetts.
Edward Joseph McKinley Edward Joseph McKinley is on the board of Clovis Oncology, Inc. He received an undergraduate degree from Yale University and an undergraduate degree from Stanford University.
Andrew R. Allen Dr. Andrew R. Allen is an Independent Director at Epizyme, Inc., an Executive Chairman at Revitope Oncology, Inc., a Member at The Royal College of Physicians and a President, Chief Executive Officer & Director at Gritstone Oncology, Inc. He is on the Board of Directors at Clovis Oncology, Inc., Sierra Oncology, Inc., Epizyme, Inc., Cell Design Labs, Inc. and Gritstone Oncology, Inc. Dr. Allen was previously employed as a Chief Medical Officer & Executive VP-Clinical by Pharmion Corp., a Head-Global Project by Abbott Laboratories, a Vice President-Oncology Drug Development by Chiron Corp., and a Principal by McKinsey & Co., Inc. He also served on the board at Nodality, Inc. He received his doctorate degree from Imperial College London.
Jim C. Blair Jim C. Blair is an entrepreneur who founded Aurora Biosciences Corp., Verus Pharmaceuticals, Inc. and Applied Biosystems, Inc. Dr. Blair is Chief Executive Officer & Director at Gene Sciences, Inc. and Partner at Domain Associates LLC, Managing Member at One Palmer Square Associates VII LLC and Managing Member at One Palmer Square Associates VI LLC (both are subsidiaries of Domain Associates LLC). Jim C. Blair is also Managing Member at One Palmer Square Associates VII LLC and Managing Member at One Palmer Square Associates VI LLC and on the board of 17 other companies. He previously occupied the position of Advisor at Mountain Group Capital LLC, Associate at White, Weld & Co. LLC, Associate of F.S. Smithers & Co., Inc., Engineering Manager at RCA Corp., Principal at Santarus, Inc., Managing Director at Rothschild, Inc., Director at Aurora Biosciences Corp., Director at Applied Biosystems, Inc. and Director at Verus Pharmaceuticals, Inc. He received an undergraduate degree from Princeton University and a graduate degree and a doctorate from the University of Pennsylvania.
Paul H. Klingenstein Mr. Paul H. Klingenstein is Independent Director at Clovis Oncology, Inc., Managing Partner at Aberdare Ventures, and a Manager at Aberdare GP III LLC. He is on the Board of Directors at Clovis Oncology, Inc., MC10, Inc., Elation EMR, Inc., and International AIDS Vaccine Initiative, Inc. He is also founder of Aberdare Ventures. He founded Aberdare Ventures in 1999. Mr. Klingenstein was previously employed as Independent Director by EnteroMedics, Inc., Independent Director by Conatus Pharmaceuticals, Inc., Independent Director by Anacor Pharmaceuticals, Inc., an Advisor by The Rockefeller Foundation, General Partner by Accel Partners LLC, and a Principal by Warburg Pincus & Co. US LLC. He also served on the board at Alibris, Inc., Ample Medical, Inc., Aviir, Inc., Aviron, Inc., Chiron Viagene, Inc., EP Technologies, Inc., Glycomed, Inc., Idun Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Medtronic Ablation Frontiers LLC, Nevro Corp., Pharmion Corp., Posit Science Corp., United Behavioral Health, VertiFlex, Inc., Xomed Medical, and Xomed Surgical Products, Inc. Mr. Klingenstein received his AB from Harvard College and his MBA from the Stanford Graduate School of Business.
Ginger L. Graham Ginger L. Graham is a businessperson who has been at the head of 6 different companies. Presently, Ms. Graham occupies the position of Chairman for Clovis Oncology, Inc. She is also on the board of 6 other companies. In her past career Ms. Graham held the position of President & Chief Executive Officer of Two Trees Consulting, President & Vice President at Vascular Intervention, Principal at Eli Lilly & Co., Director at Proteus Digital Health, Inc., Chairman of Guidant Corp., President, Chief Executive Officer & Director at Amylin Pharmaceuticals, Inc., President & Chief Executive Officer at Abbott Cardiovascular Systems, Inc., Senior Lecturer at Harvard Business School and Chairman-Scientific Council at the University of Colorado at Denver. Ms. Graham received an undergraduate degree from The University of Arkansas and an MBA from Harvard Business School.
Brian G. Atwood Founder of 6 different companies, which include: Glycomed, Inc., Versant Venture Management LLC and PE Corp. (New York), Brian G. Atwood is an entrepreneur and businessperson who has been at the head of 5 different companies and occupies the position of Chairman at Atreca, Inc. and Managing Director at Versant Venture Management LLC (which he founded in 2009), Managing Director at Versant Ventures II LLC, Managing Director at Versant Venture Capital III LP, Managing Director at Versant Ventures IV LLC, Managing Director at Versant Ventures III LLC and Managing Director at Versant Ventures I LLC (which he founded in 1999) (which are all subsidiaries of Versant Venture Management LLC). He is also on the board of Biotechnology Innovation Organization, PhaseRx, Inc., Clovis Oncology, Inc. and Spark Diagnostics, Inc. and Managing Director at Versant Ventures II LLC, Managing Director at Versant Venture Capital III LP, Managing Director at Versant Ventures IV LLC, Managing Director at Versant Ventures III LLC and Managing Director at Versant Ventures I LLC (he founded the company in 1999). In the past Brian G. Atwood occupied the position of Chairman of Five Prime Therapeutics, Inc., Chairman of Veracyte, Inc., General Partner at Brentwood Associates and General Partner for Brentwood Venture Capital (a subsidiary of Brentwood Associates), Board Member at accelerator services, Director at Cell Design Labs, Inc. (he founded the company in 2015), President & Chief Executive Officer for Glycomed, Inc. (he founded the company in 1987), Director at PE Corp. (New York) and Director at Perkin-Elmer Cetus Instruments. Mr. Atwood received a graduate degree from the University of California, Davis, an undergraduate degree from the University of California, Irvine and an MBA from Harvard Business School.
Patrick J. Mahaffy Patrick J. Mahaffy is a businessperson who founded Pharmion Corp. and Clovis Oncology, Inc. and who has been at the helm of 8 different companies. Presently, he occupies the position of Chairman for Flexion Therapeutics, Inc. and President, Chief Executive Officer & Director at Clovis Oncology, Inc. Patrick J. Mahaffy is also on the board of Lewis & Clark College (Oregon) and Boulder Community Hospital. Mr. Mahaffy previously occupied the position of Chairman for Gritstone Oncology, Inc., Chairman at Psyadon Pharmaceuticals, Inc., Chairman for Orexigen Therapeutics, Inc., President & Chief Executive Officer at NeXstar Pharmaceuticals, Inc., President & Chief Executive Officer at NeXagen, Inc., President, Chief Executive Officer & Director at Pharmion Corp., Vice President at Warburg Pincus LLC and Vice President for E.M. Warburg Pincus & Co. LLC. He received an undergraduate degree from Lewis & Clark College (Oregon) and a graduate degree from Columbia University.
Thorlef Spickschen Thorlef Spickschen is a businessperson who has been the head of 5 different companies. Dr. Spickschen is on the board of Ruprecht-Karls-Universit�0�1¤t Heidelberg, Biovision AG, Clovis Oncology, Inc. and Innovation GmbH and Chairman at German Kidney Foundation. In the past he held the position of Chairman-Supervisory Board for Biotest AG, Chairman for Boehringer Mannheim GmbH, Managing Director-Germany & Central Europe at Eli Lilly & Co., Chairman & Chief Executive Officer for Knoll AG and Chairman & Chief Executive Officer of BASF Pharma Ltd. He received a doctorate from Universit�0�1¤t zu K�0�1�0�9ln.
Michael James Barrett Michael James Barrett is a businessperson who founded Senseonics, Inc. and Genetic Therapy, Inc. and who has been at the head of 13 different companies. Currently, he is Chairman at Clovis Oncology, Inc., Chairman of Proteostasis Therapeutics, Inc. and Chairman at Psyadon Pharmaceuticals, Inc. Dr. Barrett is also Manager of NEA 12 GP LLC and Manager of NEA 11 GP LLC and on the board of 5 other companies. In the past he was Chairman of Sorrento Tech, Inc., Chairman at Galera Therapeutics, Inc., Chairman for Supernus Pharmaceuticals, Inc., Chairman of Nucleonics, Inc., Chairman for GlycoMimetics, Inc., President, Chief Executive Officer & Director at Bethesda Research Laboratories, Inc., Co-Owner at Echo Global Logistics, Inc., Co-Owner at Aradigm Corp., General Partner at NEA Management Co. LLC and General Partner for NEA Partners 10 LP (a subsidiary of NEA Management Co. LLC), Chairman & Chief Executive Officer of Genetic Therapy, Inc., President, Chief Executive Officer & Director at Life Technologies, Inc., Chief Executive Officer & Director at Senseonics, Inc., President at Smithkline Clinical Laboratories and President-In Vitro Diagnostic at GlaxoSmithKline LLC. Michael James Barrett received an undergraduate degree from Boston College, a doctorate from the University of Tennessee and an MBA from Santa Clara University.
Breanna Burkart Breanna Burkart occupies the position of Head-Investor Relations of Clovis Oncology, Inc. In the past Ms. Burkart held the position of Director-Investor Relations for Pharmion Corp.
Ann Bozeman Ann Bozeman holds the position of Executive Vice President-Human Resource at Clovis Oncology, Inc. She previously was Vice President-Human Resources of Jeppesen Sanderson, Inc. and Senior Vice President-Human Resources for Coram LLC. She received an undergraduate degree from Regis University and an undergraduate degree from Colorado Christian University.
Richard A. Fair Presently, Richard A. Fair is President, Chief Executive Officer & Director at Bellicum Pharmaceuticals, Inc. He is also on the board of Clovis Oncology, Inc. In his past career Mr. Fair was Franchise Head-Hematology at Roche Pharma Schweiz AG and SVP & Head-Therapeutic Oncology & Global Product at Genentech, Inc. Mr. Fair received an undergraduate degree from the University of Michigan and an MBA from Columbia Business School.
Keith T. Flaherty Keith T. Flaherty is an entrepreneur who founded X4 Pharmaceuticals, Inc., Strata Oncology, Inc. and X4 Pharmaceuticals, Inc. He is Associate Professor at Harvard Medical School and Director-Henri & Belinda Termeer Center at Massachusetts General Hospital Cancer Center and on the board of 5 other companies. He received an undergraduate degree from Yale University and a doctorate from The Johns Hopkins University School of Medicine.
Lindsey Rolfe Lindsey Rolfe occupies the position of Chief Medical Officer & Executive VP-Clinical at Clovis Oncology, Inc. She is also Member of The Royal College of Physicians.
Robert W. Azelby Robert W. Azelby holds the position of President, Chief Executive Officer & Director at Alder Biopharmaceuticals, Inc. He is also on the board of Clovis Oncology, Inc. and Alliance for Regenerative Medicine. In his past career Mr. Azelby was Vice President & General Manager-Oncology at Amgen, Inc. and General Manager for Amgen Europe BV (a subsidiary of Amgen, Inc.) and Chief Commercial Officer & Executive VP at Juno Therapeutics, Inc. He received an undergraduate degree from the University of Virginia and an MBA from Harvard Business School.
Keith T. Flaherty Keith T. Flaherty is an entrepreneur who founded X4 Pharmaceuticals, Inc., Strata Oncology, Inc. and X4 Pharmaceuticals, Inc. He is Associate Professor at Harvard Medical School and Director-Henri & Belinda Termeer Center at Massachusetts General Hospital Cancer Center and on the board of 5 other companies. He received an undergraduate degree from Yale University and a doctorate from The Johns Hopkins University School of Medicine.
Paul Edward Gross Presently, Paul Edward Gross is Chief Compliance Officer, General Counsel & EVP at Clovis Oncology, Inc. Mr. Gross is also on the board of Clovis Oncology UK Ltd. He previously held the position of Founding Partner of Gross Cutler Seiler Dupont LLC, Partner at Cooley LLP and Director-Business Operations at Oracle Corp. and General Counsel for Datalogix Holdings, Inc. (a subsidiary of Oracle Corp.). Mr. Gross received an undergraduate degree from United States Naval Academy and a graduate degree from UC Davis School of Law.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐